T cell Articles
-
Constitutive Expression of Tert in Thymocytes Leads to Increased Incidence and Dissemination of T-Cell Lymphoma in Lck-Tert Mice
Here we describe a new mouse model with constitutive expression of the catalytic subunit of telomerase (Tert) targeted to thymocytes and peripheral T cells (Lck-Tert mice). Two independent Lck-Tert mouse lines showed higher incidences of spontaneous T-cell lymphoma than the corresponding age-matched wild-type controls, indicating that constitutive expression of Tert promotes lymphoma. ...
-
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia (Clinical Cancer Research)
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell subset with strongintrinsic immunotherapeutic ...
-
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity CD1d can be expressed by several hematologic malignancies Bispecific Vγ9Vδ2-T cell engager Unique ability to also trigger type 1 natural killer T (NKT) ...
-
Dependence of T-lymphocyte activation on the extent of cellular damage
Mechanically damaged cells release intracellular substances, resulting in the activation of CD4- and CD8-positive T-lymphocytes. The goal of this investigation was to quantify and compare fractions of activated CD4- and CD8-positive T-lymphocytes, based on the quantity of damaged cells in a given blood sample. Blood samples were mechanically stressed by vortexing intensely. Subsequently, ...
-
Gamma delta T cells in tumor immunotherapy
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. T cells can be separated into two subpopulations based on the expression of T-cell receptors (TCRs). αβ T cells, expressing expressing αβ TCR, recognize peptide antigens, such as those ...
-
Injecting mRNA and generating CAR-T directly in the body to repair the heart in one shot
January 6, 2022—Researchers at the Perelman School of Medicine at the University of Pennsylvania published a research paper in Science titled: CAR-T cells produced in vivo to treat cardiac injury. Heart damage or inflammation can induce fibroblasts to overproduce fibrous material, causing cardiac fibrosis, which hardens the heart muscle and impairs heart function. Heart failure, liver ...
-
Science: Knockout of this epigenetic gene gives CAR-T cells the ability to continuously attack cancer cells
Simply put, CAR-T is to transform the patient's immune T cells in vitro by biotechnology, so that they recognize antigens on the surface of tumor cells, and then inject these cells back into the patient to achieve the therapeutic effect of recognizing and killing cancer cells. In 2017, CAR-T therapy was first approved by the FDA for the treatment of blood cancers such as leukemia and lymphoma. ...
-
Hair loss and defective t- and b-cell function in mice lacking orai1
ORAI1 is a pore subunit of the store-operated Ca2+ release-activated Ca2+ (CRAC) channel. To examine the physiological consequences of ORAI1 deficiency, we generated mice with targeted disruption of the Orai1 gene. The results of immunohistochemical analysis showed that ORAI1 is expressed in lymphocytes, skin, and muscle of wild-type mice and is not expressed in Orai1–/– mice. Orai1–/– mice with ...
-
New Breakthrough in Cancer Cell Research
The body's immune system is an effective weapon against disease, and immunotherapy of cancer cell research is the current frontier in the treatment of cancer and other diseases. Recently, researchers at Notre Dame University have identified specific features of the reaction of two distinct peptide antigens to a T-cell receptor (TCR), which provides new clues to optimizing molecular structure ...
-
Associations between perfluoroalkyl compounds and immune and clinical chemistry parameters in highly exposed bottlenose dolphins (Tursiops truncatus)
Perfluoroalkyl compounds (PFCs) are ubiquitous, persistent chemical contaminants found in the environment, wildlife, and humans. Despite the widespread occurrence of PFCs, little is known about the impact these contaminants have on the health of wildlife populations. We investigated the relationship between PFCs (including Σperfluorocarboxylates, Σperfluoroalkyl sulfonates, perfluorooctane ...
-
The ins and outs of TCR-T cell therapy
Adoptive cell transfer (ACT) therapy is one of the most effective therapeutic options for tumor immunotherapy that is currently emerging in clusters. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, ...
-
CAR-T Cell Anti-Cancer Therapy Ushered in A Revolutionary Breakthrough!
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. In particular, CAR-T therapy, which has been approved by the FDA, is rewriting the treatment paradigm of some hematological tumors. However, adoptive T cell therapy remains of little success in solid tumors. The main reason is that ...
-
Immune Strategies for Cancer Treatment
In the search for innovative and effective ways to target cancer, we are faced with more than just a challenging problem; we are faced with our own cells as opponents. Cancer cells evolve to achieve an optimum of physical fitness, giving them an array of abilities that no cell should possess in a healthy organism. One way to find novel therapies against cancer therefore could imply finding a ...
-
Preliminary evidence of efficacy from an open label trial of a therapeutic AIDS vaccine derived from the blood of HIV-positive donors
Two earlier reported studies indicated the beneficial clinical effects of THIVAC, a therapeutic HIV vaccine derived from the blood of HIV-positive donors. However, in those studies no stringent statistical analysis to support the beneficial clinical outcome was attempted. This report retrospectively analyses the effect of the therapy on the CD4 counts in 272 treated individuals who had at least ...
-
A Novel Potential Target for CAR-T Cell Therapy in Human Solid Tumors Discovered
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
-
Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
A population of NK cells expressing the activating receptor NKG2C and the maturation marker CD57 expands in response to human CMV (HCMV) infection. CD3–CD56dimCD57+NKG2C+ NK cells are similar to CD8+ memory T cells with rapid and robust effector function upon restimulation, persistence, and epigenetic remodeling of the IFNG locus. Chronic antigen stimulation drives CD8+ memory T cell ...
-
Project - Sublingual IL2 (BL SLIT I)
The aim of this project is to develop low dose IL-2 for treatment of early onset juvenile Type I diabetes. Low dose injectable IL-2 in animal models has been shown to restore the balance between regulatory and effector T cells and, in this way, can help to reverse autoimmunity and the development of type I diabetes. Looking ahead, we anticipate that having a suitable oral formulation of IL-2 to ...
By BioLingus AG
-
Effect of interferon receptor pathway on CAR-T cell-mediated killing of solid tumors
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
-
Beyond Insulin: Immunotherapy for Type 1 Diabetes-PI
Type 1 diabetes (T1D) is a complex T-cell-mediated autoimmune disease that results in the destruction of insulin-producing beta cells and inadequate insulin secretion. Prior to the discovery of insulin in 1921, patients with T1D died within a year or two of diagnosis. Since the discovery and mass production of insulin, T1D is no longer a terminal disease. However, over time, many patients still ...
-
IL-2 and IL-2 Receptor Series: Pioneering Solutions for Immunotherapy Research
Interleukin-2 (IL-2) is a 15kDa secretory protein with a 4-alpha-helical bundle structure. As a T-cell related growth factor, IL-2 can enhance the killing activity of NK cells and promote B cells to produce immunoglobulins. In addition, it aids in the development of regulatory T cells (Tregs), thereby producing peripheral T cell immune tolerance, as well as regulating the proliferation and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you